ConductScience.org, home

Paper8599861

Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.

Bhagwatwar HP and 3 others. Cancer Chemother Pharmacol, 1996. Cited by 76 papers, by iCite.

Cite this record

ConductScience Library. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Papers, record 8599861. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8599861

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1996
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
76
iCite
Relative citation ratio, by iCite
2.83
iCite
Revised in PubMed
2026-10-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bhagwatwar HPH P
2Phadungpojna SS
3Chow DSD S
4Andersson BSB S

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Agents, AlkylatingMajor topic
BusulfanMajor topic
Acetamides
Animals
Cell Survival
Chemistry, Pharmaceutical
Drug Stability
HL-60 Cells
Hemolysis
Humans
Injections, Intravenous
Kinetics
Male
Osmolar Concentration
Polyethylene Glycols
Rats
Solubility
Solvents
Water

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P01 CA55164NCI NIH HHSUnited StatesP01CA055164PubMed and NIH

Source NIH RePORTER

Download CSV of grants

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1288488Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.Blood1979https://conductscience.org/library/papers/288488PubMed
22591002Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2591002PubMed
33068034Preclinical toxicology and pharmacology of dimethylacetamide, with clinical notes.Drug Metab Rev1988https://conductscience.org/library/papers/3068034PubMed
42659102Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.Blood1989https://conductscience.org/library/papers/2659102PubMed
52791192Pharmacokinetics of high-dose busulfan in children.Cancer Chemother Pharmacol1989https://conductscience.org/library/papers/2791192PubMed
614076497USE OF NONAQUEOUS SOLVENTS IN PARENTERAL PRODUCTS.J Pharm Sci1963https://conductscience.org/library/papers/14076497PubMed
72824032Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors.Cancer Res1987https://conductscience.org/library/papers/2824032PubMed
89518161Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples.J Chromatogr B Biomed Sci Appl1997https://conductscience.org/library/papers/9518161PubMed
95235190Chronic granulocytic leukaemia: comparison of radiotherapy and busulphan therapy. Report of the Medical Research Council's working party for therapeutic trials in leukaemia.Br Med J1968https://conductscience.org/library/papers/5235190PubMed
104900650Chemotherapy of chronic myelocytic leukemia.Semin Hematol1969https://conductscience.org/library/papers/4900650PubMed
113523241Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.N Engl J Med1986https://conductscience.org/library/papers/3523241PubMed
126933002Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.Cancer Res1980https://conductscience.org/library/papers/6933002PubMed
132653406Marrow transplantation following busulfan and cyclophosphamide for chronic myelogenous leukaemia in accelerated or blastic phase.Br J Haematol1989https://conductscience.org/library/papers/2653406PubMed
144612168Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia.J Natl Cancer Inst1974https://conductscience.org/library/papers/4612168PubMed
156355849Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.N Engl J Med1983https://conductscience.org/library/papers/6355849PubMed
166953987Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.Blood1982https://conductscience.org/library/papers/6953987PubMed
172060084Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.Cancer Chemother Pharmacol1991https://conductscience.org/library/papers/2060084PubMed
1814005853A phase I study of dimethylacetamide.Cancer Chemother Rep1962https://conductscience.org/library/papers/14005853PubMed
191054609Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.Blood1975https://conductscience.org/library/papers/1054609PubMed
207919328Busulfan bioavailability.Blood1994https://conductscience.org/library/papers/7919328PubMed

See all 38 referencesDownload CSV of references

Cited by28

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.

PMIDTitleJournalYearIn PapersSource
42001814The FDA-approved excipient N,N-dimethylacetamide improves survival and attenuates inflammatory pathways in a murine model of endotoxemia.Biomed Pharmacother2026https://conductscience.org/library/papers/42001814PubMed
41988138Research hotspots and trends in therapeutic drug monitoring of anticancer drugs: a 1990-2024 bibliometric analysis.Front Oncol2026https://conductscience.org/library/papers/41988138PubMed
40514011Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience.Transplant Cell Ther2025https://conductscience.org/library/papers/40514011PubMed
39271948A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT).Bone Marrow Transplant2024https://conductscience.org/library/papers/39271948PubMed
36966213Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy.Bone Marrow Transplant2023https://conductscience.org/library/papers/36966213PubMed
36710948Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.Blood Cell Ther2022https://conductscience.org/library/papers/36710948PubMed
36568145Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices.Front Oncol2022https://conductscience.org/library/papers/36568145PubMed
34206798Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/34206798PubMed
28766962Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Expert Opin Drug Metab Toxicol2017https://conductscience.org/library/papers/28766962PubMed
27722893Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.Int J Hematol2016https://conductscience.org/library/papers/27722893PubMed
27154848Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.Biol Blood Marrow Transplant2016https://conductscience.org/library/papers/27154848PubMed
26292764Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.Leuk Lymphoma2016https://conductscience.org/library/papers/26292764PubMed
22455797Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.Clin Pharmacokinet2012https://conductscience.org/library/papers/22455797PubMed
21478919Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.Bone Marrow Transplant2012https://conductscience.org/library/papers/21478919PubMed
21120188Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide.Korean J Hematol2010https://conductscience.org/library/papers/21120188PubMed
20577993Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.Environ Mol Mutagen2010https://conductscience.org/library/papers/20577993PubMed
19561406Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.Curr Opin Oncol2009https://conductscience.org/library/papers/19561406PubMed
19361744Busulfan in hematopoietic stem cell transplantation.Biol Blood Marrow Transplant2009https://conductscience.org/library/papers/19361744PubMed
18489993Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18489993PubMed
18339423Altered gene expression in busulfan-resistant human myeloid leukemia.Leuk Res2008https://conductscience.org/library/papers/18339423PubMed

See all 28 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8599861

GET https://conductscience.org/api/papers/v1/8599861/references?page=2